3H-Thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients

1991 ◽  
Vol 20 (1) ◽  
pp. 19-24 ◽  
Author(s):  
B. Valentinis ◽  
R. Silvestrini ◽  
M. G. Daidone ◽  
D. Coradini ◽  
E. Galante ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Hormone Receptors ◽  
Labeling Index ◽  
Breast Cancers ◽  
Thymidine Labeling Index

Sequential assays of hormone receptors and the tritiated thymidine labeling index in 7,12-dimethylbenz(a)anthracene-induced rat mammary cancers

1985 ◽  
Vol 15 (2) ◽  
pp. 150-159 ◽  
Author(s):  
Keisuke Araki ◽  
Masaharu Kimura ◽  
Kiyoshi Sakamoto ◽  
Reiki Nishimura ◽  
Junichi Yamashita ◽  
...  
Keyword(s):  
Hormone Receptors ◽  
Tritiated Thymidine ◽  
Labeling Index ◽  
Thymidine Labeling Index

Significance of the tritiated thymidine labeling index in breast cancers

1985 ◽  
Vol 15 (2) ◽  
pp. 144-149 ◽  
Author(s):  
Keisuke Araki ◽  
Masaharu Kimura ◽  
Kiyoshi Sakamoto ◽  
Reiki Nishimura ◽  
Masanobu Akagi
Keyword(s):  
Tritiated Thymidine ◽  
Labeling Index ◽  
Breast Cancers ◽  
Thymidine Labeling Index

scholarly journals CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2872
Author(s):  
Aaron R. Waddell ◽  
Haojie Huang ◽  
Daiqing Liao
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Tumor Growth ◽  
Signaling Pathways ◽  
Cell Cycle Progression ◽  
Hormone Receptors ◽  
Steroid Hormone Receptors ◽  
Breast Cancers ◽  
Creb Binding Protein ◽  
Breast And Prostate Cancer

The CREB-binding protein (CBP) and p300 are two paralogous lysine acetyltransferases (KATs) that were discovered in the 1980s–1990s. Since their discovery, CBP/p300 have emerged as important regulatory proteins due to their ability to acetylate histone and non-histone proteins to modulate transcription. Work in the last 20 years has firmly established CBP/p300 as critical regulators for nuclear hormone signaling pathways, which drive tumor growth in several cancer types. Indeed, CBP/p300 are critical co-activators for the androgen receptor (AR) and estrogen receptor (ER) signaling in prostate and breast cancer, respectively. The AR and ER are stimulated by sex hormones and function as transcription factors to regulate genes involved in cell cycle progression, metabolism, and other cellular functions that contribute to oncogenesis. Recent structural studies of the AR/p300 and ER/p300 complexes have provided critical insights into the mechanism by which p300 interacts with and activates AR- and ER-mediated transcription. Breast and prostate cancer rank the first and forth respectively in cancer diagnoses worldwide and effective treatments are urgently needed. Recent efforts have identified specific and potent CBP/p300 inhibitors that target the acetyltransferase activity and the acetytllysine-binding bromodomain (BD) of CBP/p300. These compounds inhibit AR signaling and tumor growth in prostate cancer. CBP/p300 inhibitors may also be applicable for treating breast and other hormone-dependent cancers. Here we provide an in-depth account of the critical roles of CBP/p300 in regulating the AR and ER signaling pathways and discuss the potential of CBP/p300 inhibitors for treating prostate and breast cancer.

scholarly journals The Roles of DNA Demethylases in Triple-Negative Breast Cancer

2021 ◽  
Vol 14 (7) ◽  
pp. 628
Author(s):  
Shoghag Panjarian ◽  
Jean-Pierre J. Issa
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Tumor Suppressor Genes ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Breast Cancers ◽  
Therapeutic Implications ◽  
High Propensity ◽  
Dna Methylation Profile

Triple-negative breast cancers (TNBCs) are very heterogenous, molecularly diverse, and are characterized by a high propensity to relapse or metastasize. Clinically, TNBC remains a diagnosis of exclusion by the lack of hormone receptors (Estrogen Receptor (ER) and Progesterone Receptor (PR)) as well as the absence of overexpression and/or amplification of HER2. DNA methylation plays an important role in breast cancer carcinogenesis and TNBCs have a distinct DNA methylation profile characterized by marked hypomethylation and lower gains of methylations compared to all other subtypes. DNA methylation is regulated by the balance of DNA methylases (DNMTs) and DNA demethylases (TETs). Here, we review the roles of TETs as context-dependent tumor-suppressor genes and/or oncogenes in solid tumors, and we discuss the current understandings of the oncogenic role of TET1 and its therapeutic implications in TNBCs.

Increased tritiated thymidine-labeling index of bone marrow myeloblasts following BCG administration in man

1978 ◽  
Vol 4 (3) ◽  
pp. 197-199
Author(s):  
M. Rozencweig ◽  
P. Stryckmans ◽  
J.P. Fichefet ◽  
Mireille Socquet
Keyword(s):  
Bone Marrow ◽  
Tritiated Thymidine ◽  
Labeling Index ◽  
Thymidine Labeling Index

scholarly journals Practical Approach to Triple-Negative Breast Cancer

2017 ◽  
Vol 13 (5) ◽  
pp. 293-300 ◽  
Author(s):  
Vijayakrishna K. Gadi ◽  
Nancy E. Davidson
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Early Stage ◽  
Management Strategies ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Epidermal Growth ◽  
Proven Method

Triple negative is a term applied to breast cancers that do not meaningfully express the estrogen or progesterone hormone receptors or overexpress the human epidermal growth factor receptor 2 tyrosine kinase. At present, the only proven method for systemic management of triple-negative breast cancer for both early-stage and metastatic settings is cytotoxic chemotherapy. Here, we provide a comprehensive review of management strategies that are best supported by available data. We also review recent advances most likely to affect treatment of triple-negative breast cancer in the coming years with particular emphasis on targeted agents, biologics, and immunotherapy.

Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy

Oncology ◽  
2000 ◽  
Vol 60 (1) ◽  
pp. 88-93 ◽  
Author(s):  
Paolo Pronzato ◽  
Paola Queirolo ◽  
Stefania Vecchio ◽  
Rita Lionetto ◽  
Lucia Del Mastro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Labeling Index ◽  
Perioperative Chemotherapy ◽  
Breast Cancer Patients ◽  
Index Analysis ◽  
Thymidine Labeling Index ◽  
To Receive

scholarly journals A simple rapid autoradiography for3H-thymidine labeling index and its application to therapy of adult acute leukemia

Cancer ◽  
1980 ◽  
Vol 46 (10) ◽  
pp. 2298-2307 ◽  
Author(s):  
Takashi Yoshida ◽  
Ken-Ichi Hattori ◽  
Shinobu Nakamura ◽  
Eiichi Mitamura ◽  
Saburo Kobayashi ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Labeling Index ◽  
Thymidine Labeling Index
Sign in / Sign up

Export Citation Format

Share Document